Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Michael O'Riordan

May 01, 2025

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

FDA Approves TriClip TEER Device for Tricuspid Repair

L.A. McKeown

April 02, 2024

News Daily News

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

L.A. McKeown

February 02, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Daily News

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

Shelley Wood

September 20, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

Shelley Wood

June 01, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

Advertisement

January 2026 Dispatch for the CV Team

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Evolocumab Gains Expanded Indication for Primary Prevention

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

FDA Approves TAVI for Asymptomatic Patients With Severe Aortic Stenosis

Acoramidis Approved in Europe for ATTR Cardiomyopathy

June 2024 Dispatch for the CV Team

FDA Approves TriClip TEER Device for Tricuspid Repair

FDA Approves First Transcatheter Tricuspid Valve Replacement Device

Top Endovascular News of 2023

FDA Approves Portico TAVI Valve, Paving the Way for Third US Device

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

FDA Approves Dapagliflozin for CKD Patients

FDA Approves Vericiguat for High-risk Patients With HF

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Expands TAVR Indication to Low-Risk Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

TCTMD’s Top 10 Most Popular Stories for January 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content